T. Rowe Price Associates’s Biolase, Inc. BIOL Stock Holding History

T. Rowe Price Associates’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1	Closed	-$11K	–	2620
2017 Q3	$11K	Hold	1	–	–	﹤0.01%	2565
2017 Q2	$17K	Hold	1	–	–	﹤0.01%	2549
2017 Q1	$24K	Hold	1	–	–	﹤0.01%	2560
2016 Q4	$24K	Hold	1	–	–	﹤0.01%	2540
2016 Q3	$31K	Hold	1	–	–	﹤0.01%	2512
2016 Q2	$20K	Hold	1	–	–	﹤0.01%	2504
2016 Q1	$23K	Hold	1	–	–	﹤0.01%	2491
2015 Q4	$15K	Hold	1	–	–	﹤0.01%	2509
2015 Q3	$16K	Hold	1	–	–	﹤0.01%	2505
2015 Q2	$30K	Hold	1	–	–	﹤0.01%	2518
2015 Q1	$35K	Hold	1	–	–	﹤0.01%	2523
2014 Q4	$46K	Hold	1	–	–	﹤0.01%	2516
2014 Q3	$43K	Hold	1	–	–	﹤0.01%	2525
2014 Q2	$38K	Hold	1	–	–	﹤0.01%	2515
2014 Q1	$42K	Hold	1	–	–	﹤0.01%	2488
2013 Q4	$49K	Hold	1	–	–	﹤0.01%	2459
2013 Q3	$33K	Hold	1	–	–	﹤0.01%	2448
2013 Q2	$61K	Buy	+1	New	+$55.9K	﹤0.01%	2388

Other funds holding BIOL

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

TMC

Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return

Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates's BIOL Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Biolase, Inc. (BIOL) in Q4 2017, closing a stake of 1 share — an estimated $11K sold.

T. Rowe Price Associates first reported a position in BIOL in Q2 2013 and held it in 18 quarters. The position peaked at $61K in Q2 2013. 24 funds tracked by Wall St. Rank hold BIOL as of Q4 2017.

T. Rowe Price Associates reported no remaining Biolase, Inc. position as of Q4 2017 after selling out during the quarter.
T. Rowe Price Associates sold 1 Biolase, Inc. share in Q4 2017, an estimated $11K.
T. Rowe Price Associates first reported a position in Biolase, Inc. in Q2 2013 and held it in 18 quarters.
T. Rowe Price Associates's Biolase, Inc. position peaked at $61K in Q2 2013.
24 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.